NCT03387683View on ClinicalTrials.gov

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

dapagliflozin

dapagliflozin 10mg

DRUG

placebo

placebo to match dapagliflozin

Trial Locations (2)

20520

Research Site, Turku

SE-751 85

Research Site, Uppsala

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY